Eli Lilly and Co

Eli Lilly and Co maintains a capital structure with a debt-to-equity ratio of 2.05, indicating a significant reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.35, suggesting it has sufficient short-term assets to cover its short-term liabilities, but not with a large margin of safety. The company's price-to-book ratio is 74.11, and its price-to-tangible-book ratio is also 74.11, indicating that the market is valuing the company's equity at a premium relative to its book value. In terms of profitability, Eli Lilly and Co has a return on equity (ROE) of 17.51%, which is a strong indicator of the company's ability to generate profits from shareholders' equity. However, its return on assets (ROA) is 3.51%, which is relatively low, suggesting that the company is not efficiently utilizing its assets to generate profits. The company's gross profit margin is 81.0%, and its operating margin is 28.6%, both of which are strong compared to industry norms. Eli Lilly and Co's revenue is primarily concentrated in the United States, with a significant portion of its sales coming from this region. The company's exposure to international markets is limited, which could be a risk factor in the event of economic or political instability in the U.S.. The company's revenue concentration in a single geographic region may also limit its growth potential in other parts of the world. The company's growth trajectory is expected to remain strong, with a projected increase in revenue for the current fiscal year. The company's capital expenditure is negative, indicating that it is generating more cash from operations than it is spending on capital investments. This suggests that the company is in a position to reinvest in its business or return value to shareholders. The company's free cash flow is $391.5 million, which is a positive sign for its financial health. Eli Lilly and Co faces several risk factors, including liquidity risk due to its high debt-to-equity ratio and the fact that its net cash is negative after subtracting total debt. The company's dilution risk is assessed as low, indicating that there is a minimal likelihood of new shares being issued that could dilute existing shareholders' ownership. The company's risk assessment also highlights the importance of monitoring its liquidity position, as any significant changes could impact its ability to meet short-term obligations. Recent events, including analyst estimates and price targets, suggest that the market has a generally positive outlook on Eli Lilly and Co. The mean price target is $1,202.56, and the median price target is $1,250.00, indicating that analysts expect the stock to appreciate in value. The company has received a strong number of buy and strong-buy recommendations, which further supports the positive sentiment.